HLA donor-specific antibody and non-HLA antibody testing
Evidence level: abstract-only observational studies
Testing for donor-specific and non-HLA antibodies is studied for its association with CLAD, with reported associations in cohorts.
As of . Primary source: Tikkanen et al. 2016 (DOI).
Summary
According to the abstracts read, a cohort of 340 recipients (centre not named in the abstract) found that de novo DQ donor-specific antibodies were associated with about a twofold higher hazard of CLAD, and a cohort of 362 recipients (centre not named in the abstract) found that persistent and transient donor-specific antibodies were associated with shorter CLAD-free survival, mostly against HLA-DQ. A KU Leuven nested case-control study reports persistent donor-specific antibodies and antibody-mediated rejection as strongly associated with later RAS. A Toronto study of 89 recipients reports that autoantibodies against lung-enriched targets and de novo donor-specific antibodies conferred increased CLAD risk, and a Toronto tissue study measured DSA by Luminex and non-HLA antibodies by antigen microarray in cultured CLAD lung tissue. A five-centre study of 226 recipients reports an association of a non-HLA antibody panel with CLAD. The abstracts describe associations in observational studies and do not give testing schedules or thresholds, and this record gives no advice.
Sources and links
Related
Links from this record
- supports: De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation
- supports: Donor-specific and -nonspecific HLA antibodies and outcome post lung transplantation
- supports: Clinical predictors for restrictive allograft syndrome: A nested case-control study.
- supports: Humoral immunity to lung antigens early post-transplant confers risk for chronic lung allograft dysfunction.
- supports: Local intragraft humoral immune responses in chronic lung allograft dysfunction.
- supports: Chronic lung allograft dysfunction is associated with an increased number of non-HLA antibodies
- related to: Humoral (antibody-mediated) alloimmunity
- related to: Autoantibodies
Linked from (derived)
- measured by: Antibody-mediated rejection and donor-specific antibodies
- discusses: International Society for Heart and Lung Transplantation Scientific Statement on pulmonary antibody-mediated rejection and proposed graft, antibody, and pathology (GAP) definition
- reports use of: Chronic lung allograft dysfunction after lung transplantation: prevention, diagnosis and treatment in 44 European centres
- discusses: Novel biomarkers of chronic lung allograft dysfunction: is there anything reliable?
- discusses: Global approaches to chronic lung allograft dysfunction: Toward evidence-based harmonization
- affects: Pulmonary antibody-mediated rejection has dismal outcomes and no established treatment platform
Known gaps in this record
- consensus statements on antibody monitoring (not opened)
- assay thresholds and testing schedules (not in the abstracts)
- full text of all sources
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.